Skip to main content

Infectious Diarrhoea

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cosmo Pharmaceuticals
Cosmo PharmaceuticalsIreland - Dublin
1 program
400 mg Rifamycin SV dosagePHASE_21 trial
Active Trials
NCT03447821Completed40Est. Jul 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Cosmo Pharmaceuticals400 mg Rifamycin SV dosage

Clinical Trials (1)

Total enrollment: 40 patients across 1 trials

NCT03447821Cosmo Pharmaceuticals400 mg Rifamycin SV dosage

Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

Start: Feb 2008Est. completion: Jul 200840 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.